UPDATE 1-Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review

Pfizer Inc.

Pfizer Inc.

PFE

0.00

Adding comment from Innovent spokesperson and info on medicine approvals

SHANGHAI, June 29 (Reuters) - Pfizer's PFE.N ecnoglutide and Innovent Biologics' 1801.HK mazdutide have passed a preliminary review to be potentially included in China's basic medical insurance drug catalogue, a list published by the National Healthcare Security Administration showed on Monday.

The two drugs, which belong to the class of GLP-1 receptor agonist drugs, are both approved in China as treatments for weight management and type II diabetes.

A spokesperson for Pfizer did not immediately respond to a request for comment.

A spokesperson for Innovent told Reuters that in terms of medical insurance coverage in China only treatment for diabetes could be considered.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.